Alex Schurer
@alexkschurer.bsky.social
MD/PhD student studying leukemia stem cells & hematopoiesis
Reposted by Alex Schurer
So excited that our collaboration with the Shechter lab on a new targetable PTM -glutamylation- on NPM1c in AML is now on BioRxiv! Team effort led by @alexkschurer.bsky.social and @humaira2204.bsky.social! 🧪🩸
April 10, 2025 at 8:48 PM
So excited that our collaboration with the Shechter lab on a new targetable PTM -glutamylation- on NPM1c in AML is now on BioRxiv! Team effort led by @alexkschurer.bsky.social and @humaira2204.bsky.social! 🧪🩸
Reposted by Alex Schurer
Many years of effort by @alexkschurer.bsky.social and @humaira2204.bsky.social , following initial work by Maxim Maron, lead us to this discovery. /2
April 10, 2025 at 2:35 PM
Many years of effort by @alexkschurer.bsky.social and @humaira2204.bsky.social , following initial work by Maxim Maron, lead us to this discovery. /2
Reposted by Alex Schurer
We discovered a new AML vulnerability:
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia
NPM1-mutated acute myeloid leukemia (AML) is defined by aberrant cytoplasmic localization of the mutant NPM1c protein, and therapeutic strategies targeting this specific disease remain limited. Here, ...
bit.ly
April 10, 2025 at 2:35 PM
We discovered a new AML vulnerability:
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
Reposted by Alex Schurer
Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM!
@alexkschurer.bsky.social
@gritsmanlab.bsky.social
academic.oup.com/stcltm/advan...
@alexkschurer.bsky.social
@gritsmanlab.bsky.social
academic.oup.com/stcltm/advan...
Targeting chromatin modifying complexes in acute myeloid leukemia
Abstract. Acute myeloid leukemia (AML) is a devastating hematologic malignancy with high rates of relapse, which can, in part, be attributed to the dysregu
academic.oup.com
December 4, 2024 at 3:20 AM
Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM!
@alexkschurer.bsky.social
@gritsmanlab.bsky.social
academic.oup.com/stcltm/advan...
@alexkschurer.bsky.social
@gritsmanlab.bsky.social
academic.oup.com/stcltm/advan...